SCHEMBL2195865

SCHEMBL2195865

O=C(c1[nH]c2ccccc2c1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.51
MAPK14 Q16539 2/20 0.51
FAAH O00519 2/20 0.50
LMNA P02545 6/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194252 0.97 HTT (0.47) HTTMAPK14FAAHLMNACA12
SCHEMBL2192800 0.92 TACR3 (0.48) HTTMAPK14FAAHLMNACA12
SCHEMBL2190431 0.91 MEN1 (0.51) HTTMAPK14FAAHTUBB4ATUBB
SCHEMBL2194669 0.90 MEN1 (0.49) HTTMAPK14FAAHLMNACA12
SCHEMBL2193903 0.90 DRD2 (0.51) HTTFAAHLMNATUBB4ATUBB
SCHEMBL2192904 0.87 KMT2A (0.56) HTTLMNACYP1A2CYP2C19ALDH1A1
SCHEMBL2192919 0.86 PTGS2 (0.50) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2194692 0.85 GRIN2D (0.51) MAPK14CA12CA1CA2CA7
SCHEMBL2194985 0.85 ALDH1A1 (0.48) FAAHLMNATUBB4ATUBBTUBA3C
SCHEMBL2197250 0.84 GRIN2D (0.46) FAAHLMNACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172244-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-07-14 US claimed
EP-2252586-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-11-24 EP claimed
WO-2009105722-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-08-27 WO claimed
US-20110172244-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-07-14 US disclosed
US-20110172244-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-07-14 US disclosed
US-20110172244-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-07-14 US disclosed
EP-2252586-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-11-24 EP disclosed
WO-2009105722-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172244-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 HTT 2074/4885MAPK14 2954/4885FAAH 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.